Financial News
Latest News about Biotech
Recent news which mentions Biotech
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
September 17, 2024
From Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
September 16, 2024
From Benzinga
From Benzinga
Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss
September 16, 2024
From Benzinga
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
September 16, 2024
From Benzinga
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
September 16, 2024
From Benzinga
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
September 16, 2024
From Benzinga
Bayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging Data From Pivotal Study
September 16, 2024
From Benzinga
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
September 16, 2024
From Benzinga
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
September 16, 2024
From Benzinga
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
September 13, 2024
From Benzinga
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus
September 13, 2024
From Benzinga
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint
September 13, 2024
From Benzinga
Biotech raises $315 million in IPO, surpassing $250M target
September 13, 2024
From Business Journals
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
September 13, 2024
From Benzinga
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
September 12, 2024
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
